Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: Primary care

Audioconference: Management of Fibromyalgia

  |  

Tremendous progress is being made in the area of fibromyalgia,” says Dan Clauw, MD, professor of medicine in the division of rheumatology at the University of Michigan in Ann Arbor and moderator of the March 14 audioconference on the current management of fibromyalgia. “However,” he continues, “as in many fields of medicine, those who are not directly involved in fibromyalgia research and treatment are not aware of the progress that has been made.”

CMS to Implement AI-Based Model to Streamline Prior Authorization

  |  

Last week, the Centers for Medicare & Medicaid Services (CMS) announced that it is implementing a new prior authorization model called the Wasteful and Inappropriate Services Reduction (WISeR) Model. This six-year model, starting on Jan. 1, 2026, aims to reduce fraud, waste and abuse in traditional Medicare by using technology-enabled processes for prior authorization and…

One Rheumatologist’s Sabbatical for Contemplative Leisure

Daniel F. Battafarano, DO, MACP, MACR  |  

The year before my hike, I was extremely busy with various ACR workforce issues; meetings; presentations, locally, regionally and nationally; juggling medical missions and more. However, I had blocked time in my calendar over one year in advance to hike the Camino de Santiago in Spain with a long-time U.S. Army buddy. I met Pat…

FDA Approvals: Lupus Nephritis

  |  

Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…

Trials Find Potential Treatments for SLE, Lupus Nephritis

  |  

In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…

Case Report: Lupus Nephritis, or a Mimic?

Matthew J. Mandell, DO, FACP, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD  |  

Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involvement. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis. We present…